The Draths Corp., an Okemos Mich.-based “green” bio-chemical engineering company, has secured $2.5 million of a $5 million Series B round from Khosla Ventures, according to a regulatory filing. The company aims to produce a key building block to anti-influenza drug Tamiflu, and also to develop new anti-influenza drugs to deal with potential viral resistance.
Samir Kaul of Khosla Ventures has taken a board seat.
Draths Corp. previously had received a $1 million seed investment from Brad Greenspan, former chairman and CEO of Intermix Media (i.e., MySpace). Greenspan also sits on the Draths board of directors. www.drathscorporation.com